Pasithea Therapeutics (KTTA)
(Delayed Data from NSDQ)
$6.60 USD
+0.10 (1.54%)
Updated May 17, 2024 12:38 PM ET
After-Market: $6.82 +0.22 (3.33%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Pasithea Therapeutics Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 15 | 5 | 0 | 0 |
Income After Depreciation & Amortization | -16 | -15 | -5 | 0 | 0 |
Non-Operating Income | 0 | 3 | 2 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -16 | -14 | -2 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -16 | -14 | -2 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -16 | -14 | -2 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -15 | -5 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -16 | -15 | -5 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.23 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -12.64 | -99,999.00 | NA | NA | NA |
Diluted Net EPS (GAAP) | -13.01 | -11.00 | -4.20 | NA | NA |
Fiscal Year end for Pasithea Therapeutics Corp falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 4.04 | 5.15 | 3.78 | 3.83 | 3.22 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.04 | -5.15 | -3.78 | -3.83 | -3.22 |
Non-Operating Income | 0.18 | 0.11 | 0.18 | 0.23 | -0.05 |
Interest Expense | NA | -0.01 | 0.00 | 0.00 | 0.01 |
Pretax Income | -3.86 | -5.03 | -3.61 | -3.60 | -3.27 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.86 | -5.03 | -3.61 | -3.60 | -3.27 |
Extras & Discontinued Operations | NA | -0.02 | 0.00 | -0.17 | -0.27 |
Net Income (GAAP) | -3.86 | -5.05 | -3.61 | -3.76 | -3.54 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 1.26 | NA | NA |
Diluted EPS Before Non-Recurring Items | -99,999.00 | -99,999.00 | -2.80 | NA | NA |
Diluted Net EPS (GAAP) | -3.70 | -4.61 | -2.80 | -3.00 | -2.60 |